Revolutionary In-Body CAR-T therapy targets autoimmune diseases
NCT ID NCT07413341
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment called TI-0032-III for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard care. The treatment uses a special injection to create CAR-T cells inside the body, which then target and destroy faulty B cells that cause the disease. The main goal is to check safety, with a small group of 12 participants, and it is not yet proven to be a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED SYSTEMIC VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Changzheng Hospital
RECRUITINGShanghai, Shanghai Municipality, 200003, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can skin biopsies unlock new treatments for scleroderma?
- Could a skin patch ease stomach pain in scleroderma?
- Could a painless microneedle pad ease Raynaud's in scleroderma?
- Can a Three-Drug combo quiet lupus kidney flares?
- Can a new antibody tame lupus flares?
- Can a new pill ease the hardening skin of systemic sclerosis?